Wednesday, May 31, 2017

BRIEF-Tapimmune says on track to achieve 50 pct enrollment in ongoing phase 2 dosing study of TPIV 200

* Tapimmune provides first quarter 2017 corporate and clinical update

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)